Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "chronic" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-15 z 48
Tytuł:
What does post-exercise proteinuria tell us about kidneys?
Autorzy:
Wołyniec, Wojciech
Ratkowski, Wojciech
Zorena, Katarzyna
Januszczyk, Jacek
Kuźbicka, Karolina
Urbański, Robert
Tkachenko-Rita, Patrycja
Renke, Marcin
Rachoń, Dominik
Powiązania:
https://bibliotekanauki.pl/articles/1054979.pdf
Data publikacji:
2016
Wydawca:
Uniwersytet Szczeciński. Wydawnictwo Naukowe Uniwersytetu Szczecińskiego
Tematy:
albuminuria
chronic kidney disease
health
running
Opis:
Objectives. Post exercise proteinuria (PEP) is found in about 20–40% of sportsmen after intensive exercise. Urinary NGAL is a new marker of tubulointerstitial kidney damage. The relationship between PEP and uNGAL has not been defined yet. In presented study a resting uNGAL as a predictor of PEP was analyzed. The changes of albuminuria after exercise were monitored to estimate a frequency and range of PEP. Methods. 40 amateur healthy runners (mean age 36.65 ±10.61 years) participating in 10-km run took part in the study. Before and after the competition urine was collected. NGAL, albumin and creatinine were subsequently measured in urine. uNGAL to creatinine ratio (NCR) and albumin to creatinine ratio (ACR) were calculated. Results. 28 participants (mean age 37.9 ±11.46, 19 M, 9 F) with uNGAL below 15 ng/ml before competition were analyzed. The increase of ACR was observed in every case. Mean post-exercise ACR was 104.55 ±123.1 mg/g and was significantly higher than pre-exercise ACR 6.33 ±5.86 mg/g (p < 0.0005). The positive correlation was found between resting NCR and post-exercise ACR (r = 0.60, p < 0.05). Conclusions. Resting uNGAL positively correlated with PEP. The possible explanation of these findings is that persons with PEP had some early, occult tubulointersitial kidney damage. It is speculated that those runners have higher risk of chronic kidney disease.
Źródło:
Central European Journal of Sport Sciences and Medicine; 2016, 14, 2; 93 - 100
2300-9705
2353-2807
Pojawia się w:
Central European Journal of Sport Sciences and Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Aliskiren - an antihypertensive renin inhibitor in the treatment of patients with chronic kidney disease
Autorzy:
Łukawski, Krzysztof
Baranowicz-Gąszczyk, Iwona
Powiązania:
https://bibliotekanauki.pl/articles/972635.pdf
Data publikacji:
2017
Wydawca:
Instytut Medycyny Wsi
Tematy:
aliskiren
chronic kidney disease
clinical studies
Opis:
Introduction. The renin-angiotensin-aldosterone system (RAAS) plays an important role in the pathogenesis of hypertension, cardiovascular diseases (CVDs) and chronic kidney disease (CKD). Drugs affecting the RAAS system, such as angiotensinconverting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), are commonly used in the treatment of hypertension and heart failure. These drugs are also effective in reducing proteinuria and may, at least, delay end-stage renal disease in both diabetic and non-diabetic proteinuric CKD. However, novel drugs are needed to more effectively suppress the RAAS system and the progression of CKD. Aliskiren is the first direct renin inhibitor which has been approved for the treatment of hypertension. Additionally, a number of clinical studies have shown the antiproteinuric effect of aliskiren. Objective. This review focuses on the antihypertensive and antiproteinuric effects of aliskiren in patients with CKD. The pharmacology of aliskiren in these patients is also provided. Conclusions. Aliskiren-based hard endpoint large trials in non-diabetic nephropathy are needed in order to clarify the use of aliskiren in CKD patients.
Źródło:
Journal of Pre-Clinical and Clinical Research; 2017, 11, 1; 81-85
1898-2395
Pojawia się w:
Journal of Pre-Clinical and Clinical Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The use of over-the-counter analgesics in patients with chronic kidney disease
Autorzy:
Jakimowicz-Tylicka, Marzena
Chmielewski, Michał
Kuźmiuk-Glembin, Izabella
Skonieczny, Piotr
Dijakiewicz, Grażyna
Zdrojewska, Grażyna
Rutkowski, Bolesław
Tylicki, Leszek
Dębska-Ślizień, Alicja
Powiązania:
https://bibliotekanauki.pl/articles/895741.pdf
Data publikacji:
2019-02-05
Wydawca:
Gdański Uniwersytet Medyczny
Tematy:
chronic kidney disease
analgesics
over-the-counter
Opis:
Background: Analgesics can be sold following medical prescription, but also as over-the-counter (OTC) medications. In patients with chronic kidney disease (CKD), their use could potentially be associated with increased risk of side-effects, due to impaired renal elimination. The aim was to evaluate the epidemiology and indications for the use of OTC analgesics, and the knowledge of their side-effects in patients with CKD. Material and methods: A cross-sectional, controlled survey on the use of OTC analgesic drugs was conducted among 180 CKD patients (stage 1-5, dialysis, kidney transplant), compared to 60 controls. Results: The proportion of patients using OTC analgesics on a regular basis was higher in the CKD group, compared to controls (18.9% vs. 10.0%, p<0.02). The major indications included musculoskeletal issues, followed by headaches and other. Subgroup analysis revealed that analgesic use was lowest among transplanted patients, in comparison to CKD stage 1-5, and dialysis subjects (10%, 20%, 26%, respectively, p=0.06). Less than half of CKD patients and controls declared any knowledge on potential side-effects of analgesic drugs (45.6% vs. 40.0%, NS). Conclusions: The use of OTC analgesics among patients with CKD is higher than in subjects without CKD, with the exception of transplanted patients. The knowledge on the potential side-effect of analgesics is limited.
Źródło:
European Journal of Translational and Clinical Medicine; 2018, 1, 2; 11-16
2657-3148
2657-3156
Pojawia się w:
European Journal of Translational and Clinical Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Anaemia in chronic kidney disease- new treatment options
Autorzy:
Żórawski, M.
Musiałowska, B.
Rudzińska, M.
Koc-Żórawska, E.
Małyszko, J.S.
Powiązania:
https://bibliotekanauki.pl/articles/1918763.pdf
Data publikacji:
2018
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
chronic kidney disease
anaemia
erythropoietin
hepcidin
iron
Opis:
In recent years anaemia has been recognized as one of the most specific and evident manifestations of chronic renal failure. In the majority of cases, renal anaemia is normocytic and normochromic with normal cellularity of bone marrow. Multiple factors contribute to the molecular origins of the anaemia of chronic kidney disease. Within those factors, the disturbances in the production of erythropoietin have the greatest impact on the disease pathogenesis. However, other components such as shortened erythrocyte survival, blood loss, iron or other nutritional deficiencies, hemolysis, the presence of uremic inhibitors of erythropoiesis among others can also significantly contribute to the occurrence of anaemia.
Źródło:
Progress in Health Sciences; 2018, 8(2); 210-214
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Analysis of relationship between UMOD polymorphisms rs13335818, rs4293393 and rs13333226 and risk of chronic kidney disease caused by chronic glomerulonephritis
Analiza związku polimorfizmów rs13335818, rs4293393 i rs13333226 genu UMOD z występowaniem przewlekłej choroby nerek na tle przewlekłego kłębuszkowego zapalenia nerek
Autorzy:
Żywiec, Joanna
Piecha, Grzegorz
Gola, Mateusz
Kiliś-Pstrusińska, Katarzyna
Więcek, Andrzej
Gumprecht, Janusz
Grzeszczak, Władysław
Powiązania:
https://bibliotekanauki.pl/articles/1035893.pdf
Data publikacji:
2017
Wydawca:
Śląski Uniwersytet Medyczny w Katowicach
Tematy:
przewlekła choroba nerek
przewlekłe kłębuszkowe zapalenie nerek
polimorfizmy genu uromoduliny
chronic kidney disease
chronic glomerulonephritis
uromodulin gene polymorphisms
Opis:
INTRODUCTION: Chronic glomerulonephritis is one of the common causes of chronic kidney disease that can lead to end-stage renal failure and the need for renal replacement therapy. Understanding the aetiology of this disease and its risk factors can help develop new methods of early diagnosis and effective therapy. Uromodulin is a protein with a broad spectrum of activity, and is involved in the key pathways that regulate kidney homeostasis. AIM OF THE STUDY: The aim of the study was to analyse the relationship between three selected polymorphisms (rs13335818, rs4293393 and rs13333226) of the uromodulin gene (UMOD) and the risk of chronic kidney disease caused by chronic glomerulonephritis. MATERIAL AND METHODS: 113 patients with chronic glomerulonephritis and eGFR < 60 ml/min/1.73 m2 (experimental group) and 196 patients from the General Outpatient Clinic without a history of renal disease and eGFR > 60 ml/min/1.73 m2 (control group) were recruited for the study. The study protocol assumed a one-time blood collection for genetic testing and serum creatinine level determination. Genetic material was isolated from the peripheral blood lymphocytes of the subjects. Genotyping of the analysed polymorphisms was performed using TaqMan SNP Genotyping Assay kits. The results were processed with statistical methods using Statistica 10 and Microsoft Office Exel 2003 software, the Mann-Whitney U test and the χ2 test. Statistical significance was adopted at p < 0.05. RESULTS: No statistically significant differences in the distribution of genotypes between the experimental and control groups were found for any of the three analysed UMOD variants. CONCLUSIONS: UMOD polymorphisms rs13335818, rs4293393 and rs13333226 are not associated with the risk of chronic kidney disease caused by chronic glomerulonephritis.
WSTĘP: Przewlekłe kłębuszkowe zapalenie nerek jest jedną z częstych przyczyn przewlekłej choroby nerek mogącej prowadzić do ich schyłkowej niewydolności i konieczności stosowania terapii nerkozastępczej. Poznanie etiologii tej choroby oraz czynników ryzyka daje nadzieję na wdrożenie nowych metod wczesnej diagnostyki i skutecznej terapii. Uromodulina jest białkiem prezentującym szerokie spektrum działań, włączonym w kluczowe szlaki warunkujące homeostazę nerek. CEL PRACY: Celem pracy była ocena związku wybranych trzech polimorfizmów (rs13335818, rs4293393 i rs13333226) genu uromoduliny (UMOD) z występowaniem przewlekłej choroby nerek na tle przewlekłego kłębuszkowego zapalenia nerek. MATERIAŁ I METODY: Do badania zrekrutowano 113 chorych z przewlekłym kłębuszkowym zapaleniem nerek i eGFR < 60 ml/min/1,73 m2 (grupa badana) oraz 196 pacjentów Poradni Ogólnej POZ bez chorób układu moczowego w wywiadzie, z eGFR > 60 ml/min/1,73 m2 (grupa kontrolna). Protokół badania przewidywał jednorazowe pobranie krwi do wykonania badań genetycznych oraz w celu oznaczenia stężenia kreatyniny w surowicy. Materiał genetyczny wyizolowano z limfocytów krwi obwodowej badanych. Genotypowanie badanych polimorfizmów przeprowadzono z wykorzystaniem zestawów TaqMan SNP Genotyping Assay. Uzyskane wyniki opracowano statystycznie na podstawie programów Statistica 10 i Microsoft Office Exel 2003 z wykorzystaniem: testu Manna-Whitneya i testu χ2. Za granice istotności statystycznej przyjęto wartości p < 0,05. WYNIKI: W zakresie żadnego z trzech badanych polimorfizmów UMOD nie stwierdzono znamiennych statystycznie różnic w rozkładzie genotypów pomiędzy grupami badaną a kontrolną. WNIOSKI: Nie wykazano związku polimorfizmów rs13335818, rs4293393 i rs13333226 genu UMOD z występowaniem przewlekłej choroby nerek na tle przewlekłego kłębuszkowego zapalenia nerek.
Źródło:
Annales Academiae Medicae Silesiensis; 2017, 71; 193-203
1734-025X
Pojawia się w:
Annales Academiae Medicae Silesiensis
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Evaluation of renal function in primary care
Autorzy:
Musiałowska, B.
Rudzińska, M.
Koc-Żórawska, E.
Żórawski, M.
Powiązania:
https://bibliotekanauki.pl/articles/1918735.pdf
Data publikacji:
2018
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
chronic kidney disease
acute kidney injury
Primary Care
Opis:
Evaluation of renal function is one of the primary tools used in treatment and monitoring kidney injury such as acute kidney injury (AKI) or chronic kidney disease (CKD) in Primary Care patients. Accompanying chronic diseases also have an impact on the assessment of renal function, treatment monitoring and adjustment of drug doses.
Źródło:
Progress in Health Sciences; 2018, 8(2); 202-205
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study
Autorzy:
Renke, Marcin
Tylicki, Leszek
Rutkowski, Przemysław
Neuwelt, Alexander
Larczyński, Wojciech
Ziętkiewicz, Marcin
Aleksandrowicz, Ewa
Łysiak-Szydłowska, Wiesława
Rutkowski, Bolesław
Powiązania:
https://bibliotekanauki.pl/articles/1040322.pdf
Data publikacji:
2010
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
proteinuria
kidney
tubular injury
chronic kidney disease
Atorvastatin
Opis:
Background. There is evidence that dyslipidemia is associated with chronic kidney disease (CKD) and it has been implicated in the progression of renal damage. Optimal management of dyslipidemia should therefore lead to renal benefits. A number of experimental models demonstrate a beneficial effect of statins in ameliorating renal damage. However, the exact mechanism by which statins protect against renal damage remains unclear. Methods. In a placebo-controlled, randomized, cross-over study we evaluated the influence of atorvastatin (ATO) 40 mg/day added to the renin-angiotensin-aldosterone systeme (RAAS) blockade on proteinuria and surrogate biomarkers of tubular damage or injury in 14 non-diabetic patients with proteinuria (0.4-1.8 g per 24 h) with normal or declined kidney function (eGFR 55-153 ml/min). In the eight-week run-in period, therapy using angiotensin converting enzyme inhibitors (ACEI) and/or angiotensin II subtype 1 receptor antagonists (ARB) was adjusted to achieve a blood pressure below 130/80 mm Hg. Next, patients were randomly assigned to one of two treatment sequences: ATO/washout/placebo or placebo/washout/ATO. Clinical evaluation and laboratory tests were performed at the randomization point and after each period of the study. The primary end point of this study was a change in proteinuria measured as 24-h urine protein excretion (DPE). Secondary end points included urine N-acetyl-β-d-glucosaminidase (NAG) and α1-microglobulin (α1m) excretion. Results. The ATO therapy significantly reduced urine excretion of α1m (p=0.033) and NAG (p=0.038) as compared to placebo. There were no differences in proteinuria, blood pressure, eGFR and serum creatinine between the ATO and placebo groups. Conclusion. Atorvastatin treatment is safe and improves biomarkers of tubular damage or injury in non-diabetic patients with CKD.
Źródło:
Acta Biochimica Polonica; 2010, 57, 4; 547-552
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Prevalence, prescription patterns, and quality of life of anaemia in adults with chronic renal disease
Autorzy:
Sandeep, Akkam
Elumalai, Karthikeyan
Williams, Helen
Salkapuram, Sunilkumar
Anandakumar, Shanmugam
Srinivasan, Sivaneswari
Powiązania:
https://bibliotekanauki.pl/articles/29520467.pdf
Data publikacji:
2023
Wydawca:
Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:
anaemia
chronic kidney disease
prescribing pattern
quality of life
Opis:
Introduction and aim. Anaemia is a chronic kidney disease (CKD) condition characterised by a decline in glomerular filtration rate (GFR) and impaired kidney function. The aim of this study was to assess the prevalence, prescribing patterns, and quality of life of anaemia in patients with chronic renal disease who were adults (>18 years of age) at a tertiary care hospital. Material and methods. Data on demographic characteristics, laboratory results, medication prescriptions, and quality of life assessments were collected. Statistical tests were performed to determine associations between anaemia prevalence and factors like age, gender, and CKD stage. The study included 132 patients, with a gender distribution of 89 men and 43 women. Results. The most frequently prescribed drugs are epoetin (15.06%), multivitamins (14.82%), iron (10.65%), folic acid (10.22%), calcium carbonate (8.17%), calcitriol (5.6%), and omeprazole (4.22%). The cardiovascular system, blood disorders, and blood-producing organs come after the gastrointestinal tract and metabolism in the first anatomical level of the ATC classification. Conclusion. It suggests hospital audits and recommendations for improved prescription practices. Further investigation into anaemia causes and drug class appropriateness is needed, and implementing improvements could potentially improve health outcomes
Źródło:
European Journal of Clinical and Experimental Medicine; 2023, 4; 785-792
2544-2406
2544-1361
Pojawia się w:
European Journal of Clinical and Experimental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Dietary supplement use among patients with chronic kidney disease
Autorzy:
Jakimowicz-Tylicka, Marzena
Chmielewski, Michał
Kuźmiuk-Glembin, Izabella
Skonieczny, Piotr
Dijakiewicz, Grażyna
Zdrojewska, Grażyna
Rutkowski, Bolesław
Tylicki, Leszek
Dębska Ślizień, Alicja
Powiązania:
https://bibliotekanauki.pl/articles/1038410.pdf
Data publikacji:
2018
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
dietary supplements
vitamins
minerals
chronic kidney disease
dialysis
toxicity
Opis:
Background. Dietary supplements (DS) are available over the counter, but patients with impaired renal function are specifically at risk for toxicity when consuming certain DS. The aim of this study was to evaluate the prevalence and characteristics of DS use in patients with chronic kidney disease (CKD). Material and methods. A cross-sectional, controlled DS use survey (22 questions) was conducted among 180 CKD patients (stage 1-5, dialysis, kidney transplant), with 60 patients without CKD serving as controls. Results. DS use did not differ significantly between subjects with and without CKD, unless the CKD patients were on dialysis. In the CKD group, 20% admitted to use DS regularly and 22% did not take the mat all. In the controls, DS consumption was 17% and 13%, respectively (NS). The DS use was higher among women ascompared to men (89% vs. 70%; p < 0.005), and people living in cities versus those living in the country side (81% vs. 63%; p < 0.05). DS most commonly used were: vitamins, minerals, and herbs. Major indications for DS use included: musculoskeletal issues, general health improvement and prevention of urinary tract infections. Subgroup analyses revealed that dialysis patients were characterized by a significantly higher DS use in comparison to CKD stage 1-5 subjects and renal transplant recipients. The decision to introduce DS was made by the physician in 54% of cases; by a pharmacist in 9% of cases, and by the patients themselves in 37%. Only 21% of patients with CKD, and 27% of subjects without CKD, declared knowledge of any possible side-effects associated with DS (NS). Conclusions. The use of DS among patients with CKD is similar to patients without CKD, with the exception of those on dialysis. Vitamins and minerals were the most commonly reported DS consumed. The knowledge on potential side-effectof DS was limited to approximately one-fourth of those surveyed.
Źródło:
Acta Biochimica Polonica; 2018, 65, 2; 319-324
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Selenium supplementation to chronic kidney disease patients on hemodialysis does not induce the synthesis of plasma glutathione peroxidase
Autorzy:
Zachara, Bronislaw
Gromadzinska, Jolanta
Zbrog, Zbigniew
Swiech, Rafal
Wasowicz, Wojciech
Twardowska, Ewa
Jablonska, Ewa
Sobala, Wojciech
Powiązania:
https://bibliotekanauki.pl/articles/1040656.pdf
Data publikacji:
2009
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
hemodialysis
selenium supplementation
glutathione peroxidase
chronic kidney disease
plasma
Opis:
Background: Numerous authors have shown that selenium (Se) concentration and glutathione peroxidase (GSH-Px) activity in plasma of chronic kidney disease (CKD) patients are lower than in healthy subjects, but there are only few publications on the level of GSH-Px protein in those patients and no reports on the effect of Se supplementation to HD patients on the level of this enzyme. Subjects and Methods: Se concentration and GSH-Px protein level in plasma were measured in a group of 30 CKD patients on hemodialysis (HD) supplemented with 200 µg Se/day for 3 months, and 28 patients on HD administered with placebo. Se concentration was measured by graphite furnace atomic absorption spectrometry and plasma GSH-Px protein level by the sandwich ELISA method using polyclonal antibody specific for human plasma GSH-Px. Results: Se concentration in patients on placebo did not change throughout the 3-month study period, but increased significantly in Se supplemented group. Se supplementation to CKD patients on HD had no effect on the level of GSH-Px protein. Conclusions: The lack of GSH-Px protein in CKD patients on HD is not linked to Se deficiency since the level of this element increased after Se supplementation while enzyme protein level did not change. The damaged kidney of HD patients is unable to synthesize GSH-Px, even after induction with selenium.
Źródło:
Acta Biochimica Polonica; 2009, 56, 1; 183-187
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study
Autorzy:
Renke, Marcin
Tylicki, Leszek
Rutkowski, Przemysław
Knap, Narcyz
Ziętkiewicz, Marcin
Neuwelt, Alexander
Aleksandrowicz, Ewa
Łysiak-Szydłowska, Wiesława
Woźniak, Michał
Rutkowski, Bolesław
Powiązania:
https://bibliotekanauki.pl/articles/1040438.pdf
Data publikacji:
2010
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
pentoxifylline
oxidative stress
kidney
chronic kidney disease
proteinuria
tubular injury
Opis:
Background: Inhibition of the renin-angiotensin-aldosterone system (RAAS) with angiotensin converting enzyme inhibitors (ACEI) and/or angiotensin II subtype 1 receptor antagonists (ARB) is a common strategy used in the management of patients with chronic kidney disease (CKD). However, there is no universal therapy that can stop progression of CKD. Pentoxifylline (PTE) is a non-specific phosphodiesterase inhibitor with anti-inflammatory properties. It has been reported to have promising effects in CKD treatment. Methods: In a placebo-controlled, randomized, cross-over study we evaluated the influence of PTE (1200 mg/day) added to RAAS blockade on proteinuria, surrogate markers of tubular injury and oxidative stress-dependent products in 22 non-diabetic patients with proteinuria (0.4-4.3 g per 24h) with normal or declined kidney function [eGFR 37-178 mL/min]. In an eight-week run-in period, therapy using ACEI and/or ARB was adjusted to achieve a blood pressure below 130/80 mm Hg. Next, patients were randomly assigned to one of two treatment sequences: PTE/washout/placebo or placebo/washout/PTE. Clinical evaluation and laboratory tests were performed at the randomization point and after each period of the study. Results: The PTE therapy reduced proteinuria (by 26%) as compared to placebo. There were no differences in α1-microglobulin, urine excretion of N-acetyl-β-d-glucosaminidase (NAG), hsCRP, the urinary excretion of 15-F2t-isoprostane, blood pressure (BP), eGFR and serum creatinine between the PTE and placebo groups. Conclusion: Pentoxifylline may decrease proteinuria in non-diabetic patients with CKD.
Źródło:
Acta Biochimica Polonica; 2010, 57, 1; 119-123
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Analysis of the association between rs12917707 and rs11864909 single nucleotide polymorphisms in the region of the uromoduline gene and chronic kidney disease - a family-based study
Autorzy:
Żywiec, Joanna
Kiliś-Pstrusińska, Katarzyna
Tomaszewski, Maciej
Grzeszczak, Władysław
Powiązania:
https://bibliotekanauki.pl/articles/990841.pdf
Data publikacji:
2017
Wydawca:
Instytut Medycyny Wsi
Tematy:
chronic kidney disease
genetic association
family-based study
umod polymorphism
Opis:
Chronic kidney disease (CKD) is an important challange for healthcare systems wordwide because of its high prevalence and serious late complications. The results of recent studies suggest an association between CKD development and genetic variation within the uromodulin gene (UMOD). The aim of this study was to investigate associations between two common single nucleotide polymorphisms – rs12917707 and rs11864909, located in the region of UMOD and chronic renal disease. The study group consisted of 109 patients with chronic kidney disease, caused by chronic renal glomerulonephritis or chronic tubulointerstitial nephritis, and 109 pairs of their biological parents. Genotyping for rs12917707 and rs11864909 was carried out using the TaqMan Pre-designed SNP Genotyping Assay. In the transsmission disequilibrium test, allele C of rs11864909 was preferentialy transmitted from parents to the children with chronic tubulointerstinal nephritis. The rs12917707 was not associated with CKD. Neither of the investigated polymorphisms was associated with the progression of chronic kidney disease. The obtained results suggest an association of rs11864909 with chronic kidney disease secondary to chronic tubulointerstinal nephritis.
Źródło:
Annals of Agricultural and Environmental Medicine; 2017, 24, 3
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Evaluation of anxiety and depression disorders and the associated factors among hemodialysis subjects
Autorzy:
Touil, Driss
Aouane, Mahjoub
Touhami Ahami, Ahmed Omar
Powiązania:
https://bibliotekanauki.pl/articles/2106018.pdf
Data publikacji:
2019-12-11
Wydawca:
Fundacja Edukacji Medycznej, Promocji Zdrowia, Sztuki i Kultury Ars Medica
Tematy:
chronic kidney disease
hemodialysis
anxiety
depression
personality
quality of life
Opis:
Identifying anxio-depressive disorders, evaluating their prevalence and determining the different factors that can intervene in their hap- pening to the patients suffering from hemodialysis. Transversal descriptive and analytical study over 70 patients, real- ized at the dialysis unit of the Idrissi regional hospital’s department of medicine at Kenitra, Morocco, over a period of three months starting from 27 March to 26 June 2015. The data were acquired from a survey and psychiatric evaluation scales: The scale HADS (Hospital Anxiety and Depression Scale ) to evaluate anxiety and depression and the scale of « Big Five French Inventory to evaluate the treats of personality» (BF-Fr). Average age was from 54,66±15,96 years. The seniority of the hemodialysis was on average 5,20±3,23 years. The studied traits of personality show a decrease regard to the average score of dimen- sion O (overture of sense) and of the dimension E score (extraversion) versus an evaluation of the dimension N score (Neu ro ticism). The prevalence of anxio-depressive troubles were as the following; 74,29% presented an anxious state (suspected or proven) and 70% had a depressive state (suspected or proven). The anxious troubles were correlated to age and to N and O characters of personality traits BFI-Fr. the depressive troubles were correlated to N charac- ters traits of personality BFI-Fr, and the anxious troubles were pos- itively correlated to depressive troubles. The prevalence of anxio-depressive troubles among hemodialysis subjects was elevated with repercussions on the personality. The involvement of a psychologist in the processes of taking charge is obligatory.
Źródło:
Acta Neuropsychologica; 2019, 17(4); 405-416
1730-7503
2084-4298
Pojawia się w:
Acta Neuropsychologica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Uromodulin – biomarker of renal function with promising clinical application
Autorzy:
Chojęta, D.
Kozioł, M.M.
Smarz-Widelska, I.
Powiązania:
https://bibliotekanauki.pl/articles/2087806.pdf
Data publikacji:
2020
Wydawca:
Uniwersytet Opolski. Instytut Nauk o Zdrowiu
Tematy:
Tamm-Horsfall protein
chronic kidney disease
acute kidney failure
Umod
Opis:
Uromodulin (also known as Tamm-Horsfall protein) is a glycoprotein produced exclusively in the kidneys, mainly in the epithelial cells of the thick ascending limb of the loop of Henle. Under physiological conditions, it is the most abundant urinary protein. A small proportion is released into the renal interstitium and then into the blood, where it can be detected and used as a potential parameter of renal function. Uromodulin has numerous physiological roles and potential pathogenetic significance, including providing protection against urinary tract infections and the formation of urinary deposits, as well as being involved in the immunomodulatory functions and regulation of water and electrolyte balance by the kidneys. Unlike classic renal markers (such as creatinine), uromodulin levels decrease with progressive renal dysfunction. A significant advantage of this parameter is therefore the detectable changes in concentration at the early stages of development of chronic kidney disease. In addition, assessment in clinical materials, such as urine and blood, is relatively simple by immunoenzymatic methods. It is evident that the quantitative determination of uromodulin in blood serum is associated with a lower risk of laboratory error and has a better correlation with renal function. Based on previous studies, Tamm-Horsfall protein / uromodulin can be considered a valuable parameter for standard diagnostics of kidney function and renal diseases. It appears that no other marker is currently able to reflect the integrity and functional state of the renal tubules as sensitively as uromodulin. Due to the potential of this parameter, the article presents and overview of the current information available about uromodulin, as well as the available diagnostic tests and the frequency of their use in clinical practice.
Źródło:
Medical Science Pulse; 2020, 14, 3; 84-90
2544-1558
2544-1620
Pojawia się w:
Medical Science Pulse
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: A review
Autorzy:
Zachara, Bronisław
Gromadzińska, Jolanta
Wąsowicz, Wojciech
Zbróg, Zbigniew
Powiązania:
https://bibliotekanauki.pl/articles/1041155.pdf
Data publikacji:
2006
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
hemodialysis
selenium
kidney transplantation
glutathione peroxidase
chronic kidney disease
antioxidants
plasma
Opis:
The metabolism of oxygen in aerobic organisms leads to generation of reactive oxygen species (ROS). These entities are able to oxidize almost all classes of macromolecules, including proteins, lipids and nucleic acids. The physiological level of ROS is usually regulated by antioxidant defense mechanisms. There are at least three groups of antioxidant enzymes: superoxide dismutases, catalases and glutathione peroxidases (GSH-Pxs) which neutralize ROS. The trace elements (copper, zinc and selenium) bound to the active sites of the above listed enzymes play an important role in the antioxidant defense system. In mammals, a major function of selenium (Se) and Se-dependent GSH-Pxs is to protect cells from oxidative stress. Selenium concentrations and GSH-Px activities are altered in blood components of chronic kidney disease (CKD) patients. The Se level is frequently lower than in healthy subjects and the concentration very often decreases gradually with advancing stage of the disease. Studies on red cell GSH-Px activity in CKD patients reported its values significantly lower, significantly higher and lower or higher, but not significantly as compared with healthy subjects. On the other hand, all authors who studied plasma GSH-Px activity have shown significantly lower values than in healthy subjects. The degree of the reduction decreases gradually with the progression of the disease. High inverse correlations were seen between plasma GSH-Px activity and creatinine level. A gradual decrease in plasma GSH-Px activity in CKD patients is due to the fact that this enzyme is synthesized predominantly in the kidney and thus the impairment of this organ is the cause of the enzyme's lower activity. Se supplementation to CKD patients has a slightly positive effect in the incipient stage of the disease, but usually no effect was observed in end-stage CKD. Presently, kidney transplantation is the only treatment that may restore plasma Se level and GSH-Px activity in patients suffering from end-stage CKD. A few studies have shown that in kidney recipients, plasma Se concentration and GSH-Px activity are restored to normal values within a period of 2 weeks to 3 months following surgery and thus it can be acknowledged that Se supplementation to those patients has a positive effect on plasma GSH-Px activity.
Źródło:
Acta Biochimica Polonica; 2006, 53, 4; 663-677
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Wyświetlanie 1-15 z 48

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies